The Scientific and Technological Research Council of Türkiye (TÜBITAK) and Marmara Research Center (MAM) launched the Medical Biotechnology Research Center (MEDIBIYO) on Tuesday to supply biotechnological medicines and vaccines on a pilot scale, in addition to medicine to fight most cancers.
Situated on the TÜBITAK MAM Gebze campus in Kocaeli province adjoining to Istanbul, the MEDIBIYO facility has the capability to supply biotechnological medicine and vaccines that adjust to good manufacturing apply (GMP) requirements. It helps many industrial institutions in Türkiye and is prepared for operation.
Since 2014, TÜBITAK has created vital momentum in establishing analysis infrastructure and creating product-oriented tasks to satisfy Türkiye’s wants within the mentioned sector.
The heart is anticipated to begin operations quickly in response to calls for from the trade and pharmaceutical firms.
Last yr, the primary biosimilar drug mission, from cell to drug, was accomplished by a partnership with the pharmaceutical trade below TÜBITAK and MAM’s supervision. Following that, an space was established to assist small-scale manufacturing.
Cancer remedy
The heart is conducting research on the manufacturing of customized wound dressings utilizing three-dimensional (3D) bioprinting know-how, the event of theranostics molecules for prognosis and remedy of stable tumors, and the event of a CAR-T cell remedy system focused at COVID-19 and CD19, amongst others.
Ongoing analysis consists of the event of a 3D lung most cancers mannequin for early detection and screening for biomarker-based lung most cancers, tissue engineering methods primarily based on mobile remedy in bone restore, nanoparticle-based molecular focused colon and lung most cancers remedy, improvement of recent dendritic nanostructures that concentrate on gene and drug carriers in colon most cancers remedy, in addition to hemostatic and tissue adhesive merchandise.
TÜBITAK was shaped by a consortium of greater than 60 nations from South Africa, Eastern Europe, the Middle East and Asia for the institution of the brand new International Center for Genetic Engineering and Biotechnology.
This heart will contribute to Türkiye’s worldwide visibility within the biotechnology sector. Preliminary analysis has begun through the signing of related agreements with the Technology Center (ICGEB), which is able to function below the framework of TÜBITAK MAM.
After Italy, South Africa, India and China, this heart goals to be the world’s prime heart for important analysis on vaccines and medicines for the biotechnology ecosystem in Eastern Europe and the Middle East areas.
Source: www.dailysabah.com
